Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia
About the study
This study evaluates the efficacy of two prescription digital therapeutics (PDT) in addition to standard of care (SOC) therapy for the treatment of experiential negative symptoms of schizophrenia in late adolescents and adults.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
A participant will be eligible for entry into the study if all of the following criteria are met:
- Has a primary diagnosis of schizophrenia.
- Is on a stable dose of antipsychotic medication(s).
- Has obtained an average score of ≥2 (moderate to severe) in at least two of the three CAINS-MAP domains (Social, Work, or Recreational).
EXCLUSION CRITERIA
Exclusion Criteria:
A participant will not be eligible for study entry if any of the following criteria are met:
- Is currently treated with more than two antipsychotic medications (including more than two dosage forms).
- Meets DSM-5, for diagnoses not under investigation.
- Has participated in a CT-155 clinical study.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study Details
Contition
Schizophrenia
Age
18+
Phase
PHASE3
Participants Needed
432
Est. Completion Date
Jul 18, 2025
Treatment Type
INTERVENTIONAL
Sponsor
Click Therapeutics, Inc.
ClinicalTrials.gov NCT Identifier
NCT05838625
Study Number
CT-155-R-001
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?